• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雷帕霉素哺乳动物靶点是甲状腺滤泡上皮中磷脂酰肌醇-3-羟基引发的增殖信号的关键效应器。

Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium.

作者信息

Yeager Nicole, Brewer Charlene, Cai Kathy Qi, Xu Xiang-Xi, Di Cristofano Antonio

机构信息

Human Genetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.

出版信息

Cancer Res. 2008 Jan 15;68(2):444-9. doi: 10.1158/0008-5472.CAN-07-3030.

DOI:10.1158/0008-5472.CAN-07-3030
PMID:18199538
Abstract

Activation of the phosphatidylinositol-3-OH kinase (PI3K) signaling cascade is becoming increasingly recognized as a common feature of thyroid follicular neoplasms. We have recently shown that conditional loss of Pten in the mouse thyroid follicular cells is sufficient to stimulate continuous autonomous growth, leading to a homogeneously hyperplastic gland and to the development of follicular adenomas. Because the PI3K/AKT cascade can activate a plethora of different signaling pathways, it is still unclear which of these may represent the key mitogenic output of PI3K-initiated signaling. Here, we show that the in vivo proliferative response to chronic PI3K activation profoundly relies on the activation of the mammalian target of rapamycin (mTOR)/S6K1 axis, and that mTOR inhibition in Pten mutant mice and cells restores virtually normal proliferation rates, despite the presence of still elevated Akt activity, at least in part by down-regulating cyclins D1 and D3, and without affecting cell survival.

摘要

磷脂酰肌醇-3-羟基激酶(PI3K)信号级联的激活日益被认为是甲状腺滤泡性肿瘤的一个共同特征。我们最近发现,小鼠甲状腺滤泡细胞中Pten的条件性缺失足以刺激持续的自主生长,导致甲状腺均匀增生以及滤泡性腺瘤的发生。由于PI3K/AKT级联可激活众多不同的信号通路,目前仍不清楚其中哪条通路可能代表PI3K起始信号的关键促有丝分裂输出。在此,我们表明,体内对慢性PI3K激活的增殖反应在很大程度上依赖于雷帕霉素哺乳动物靶标(mTOR)/S6K1轴的激活,并且在Pten突变小鼠和细胞中抑制mTOR可使增殖速率恢复到几乎正常水平,尽管Akt活性仍处于升高状态,至少部分是通过下调细胞周期蛋白D1和D3来实现的,且不影响细胞存活。

相似文献

1
Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium.雷帕霉素哺乳动物靶点是甲状腺滤泡上皮中磷脂酰肌醇-3-羟基引发的增殖信号的关键效应器。
Cancer Res. 2008 Jan 15;68(2):444-9. doi: 10.1158/0008-5472.CAN-07-3030.
2
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.在甲状腺癌小鼠模型中,抑制磷脂酰肌醇3激酶可延缓肿瘤进展并阻止转移扩散。
Carcinogenesis. 2007 Dec;28(12):2451-8. doi: 10.1093/carcin/bgm174. Epub 2007 Jul 28.
3
Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts.甲状腺激素通过磷脂酰肌醇3激酶在人成纤维细胞中诱导Akt/蛋白激酶B-雷帕霉素哺乳动物靶标-p70S6K级联反应的快速激活。
Mol Endocrinol. 2005 Jan;19(1):102-12. doi: 10.1210/me.2004-0093. Epub 2004 Sep 23.
4
Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis.小鼠甲状腺中Pten缺失导致甲状腺肿和滤泡性腺瘤:对甲状腺功能及考登病发病机制的见解
Cancer Res. 2007 Feb 1;67(3):959-66. doi: 10.1158/0008-5472.CAN-06-3524.
5
Thyroid-stimulating hormone initiated proliferative signals converge in vivo on the mTOR kinase without activating AKT.促甲状腺激素引发的增殖信号在体内汇聚于mTOR激酶,而不激活AKT。
Cancer Res. 2007 Sep 1;67(17):8002-6. doi: 10.1158/0008-5472.CAN-07-2471.
6
Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN.胚胎和新生内膜平滑肌细胞所表达的独特、高增殖性生长表型由组成型Akt、mTOR和p70S6K信号传导驱动,并被PTEN积极抑制。
Circulation. 2004 Mar 16;109(10):1299-306. doi: 10.1161/01.CIR.0000118462.22970.BE. Epub 2004 Mar 1.
7
Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/serine-threonine protein kinase B/mammalian target of rapamycin/p70 ribosomal S6 kinase 1.血清素诱导的肺动脉平滑肌生长需要磷脂酰肌醇3激酶/丝氨酸 - 苏氨酸蛋白激酶B/雷帕霉素哺乳动物靶标/p70核糖体S6激酶1的激活。
Am J Respir Cell Mol Biol. 2006 Feb;34(2):182-91. doi: 10.1165/rcmb.2005-0163OC. Epub 2005 Sep 29.
8
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.雷帕霉素哺乳动物靶点抑制可增强PTEN缺陷型和PTEN完整型胶质母细胞瘤细胞对表皮生长因子受体激酶抑制剂的反应。
Cancer Res. 2006 Aug 15;66(16):7864-9. doi: 10.1158/0008-5472.CAN-04-4392.
9
Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.滤泡性甲状腺癌表现为 PKA 和 mTOR 的双重激活,这是通过在小鼠中甲状腺特异性缺失 Prkar1a 和 Pten 来模拟的。
J Clin Endocrinol Metab. 2014 May;99(5):E804-12. doi: 10.1210/jc.2013-3101. Epub 2014 Feb 10.
10
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.雷帕霉素介导的雷帕霉素哺乳动物靶标抑制对Akt和eIF4E存活途径的激活作用。
Cancer Res. 2005 Aug 15;65(16):7052-8. doi: 10.1158/0008-5472.CAN-05-0917.

引用本文的文献

1
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.甲状腺癌的分子改变:从基础到临床实践。
Genes (Basel). 2019 Sep 13;10(9):709. doi: 10.3390/genes10090709.
2
Synergistic repression of thyroid hyperplasia by cyclin C and Pten.周期素 C 和 Pten 协同抑制甲状腺增生。
J Cell Sci. 2019 Aug 15;132(16):jcs230029. doi: 10.1242/jcs.230029.
3
Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.评估依维莫司和帕瑞肽在甲状腺癌细胞系和异种移植模型中的临床前疗效。
PLoS One. 2019 Feb 26;14(2):e0206309. doi: 10.1371/journal.pone.0206309. eCollection 2019.
4
PI3K/mTOR inhibition potentiates and extends palbociclib activity in anaplastic thyroid cancer.PI3K/mTOR 抑制增强并延长了帕博西尼在间变性甲状腺癌中的活性。
Endocr Relat Cancer. 2019 Apr 1;26(4):425-436. doi: 10.1530/ERC-19-0011. Epub 2019 Jan 1.
5
Retrospective Study of Sirolimus and Cyclophosphamide in Patients with Advanced Differentiated Thyroid Cancers.西罗莫司与环磷酰胺治疗晚期分化型甲状腺癌患者的回顾性研究
J Thyroid Disord Ther. 2015 Aug;4(3). doi: 10.4172/2167-7948.1000188. Epub 2015 Jul 17.
6
New therapies for dedifferentiated papillary thyroid cancer.去分化型甲状腺癌的新疗法。
Int J Mol Sci. 2015 Mar 17;16(3):6153-82. doi: 10.3390/ijms16036153.
7
Evaluation of PTEN, PI3K, MTOR, and KRAS expression and their clinical and prognostic relevance to differentiated thyroid carcinoma.PTEN、PI3K、MTOR和KRAS表达的评估及其与分化型甲状腺癌的临床和预后相关性
Contemp Oncol (Pozn). 2014;18(4):234-40. doi: 10.5114/wo.2014.43803. Epub 2014 Jul 4.
8
Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.甲状腺癌细胞系中癌蛋白表达后mTORC1活性信号控制的转换
J Clin Endocrinol Metab. 2014 Oct;99(10):E1976-87. doi: 10.1210/jc.2013-3976. Epub 2014 Jul 16.
9
Follicular thyroid cancers demonstrate dual activation of PKA and mTOR as modeled by thyroid-specific deletion of Prkar1a and Pten in mice.滤泡性甲状腺癌表现为 PKA 和 mTOR 的双重激活,这是通过在小鼠中甲状腺特异性缺失 Prkar1a 和 Pten 来模拟的。
J Clin Endocrinol Metab. 2014 May;99(5):E804-12. doi: 10.1210/jc.2013-3101. Epub 2014 Feb 10.
10
Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells.抑制 AMPK 和克雷布斯循环基因表达可驱动 Pten 缺陷性甲状腺前瘤细胞的代谢重塑。
Cancer Res. 2013 Sep 1;73(17):5459-72. doi: 10.1158/0008-5472.CAN-13-1429. Epub 2013 Jun 24.